Utility of the Morisky Medication Adherence Scale in gout: a prospective study [Corrigendum]

Csl, Tan; Teng, G.G.; Chong, KJ; Cheung, PP; Lim, Andrew Kean Seng; Wee, HL; Santosa, Amelia

doi:10.2147/ppa.s130333

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Using Method 1 (self‐report), 63% of our cohort were adherent (PDC ≥80%), while only 23% were adherent when the WHO DDD was used in the calculation (Method 2). The adherence rates with Method 1 concur with previous studies 34–36 . The results suggest strongly that the WHO DDD estimate exceeds actual doses employed to manage gout.…”

Section: Discussionsupporting

confidence: 85%

“…MPR is calculated similarly to PDC but not adjusted for medication dispensed prior to the start date for calculation of MPR, thereby tending to overestimate adherence in comparison to PDC 13 . Two other studies reported mean MPRs of 96% 36 and 88%, 35 with 84% 36 and 78% 37 of the study participants found to be adherent to ULT using the MPR ≥80% standard. However, recent systematic reviews and meta‐analyses based on prescription claims data 38–40 reported much lower proportions of people classified as ULT‐adherent (ranging from 10% to 48%).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

Schulz,

Coleshill,

Day

et al. 2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

AimsThe aim of this study was to estimate adherence to urate‐lowering therapy (ULT), predominately allopurinol, from Australia's Pharmaceutical Benefits Scheme (PBS) claims database in association with (1) patient‐reported doses and (2) World Health Organization's (WHO) defined daily doses (DDD), namely, allopurinol (400 mg/day) or febuxostat (80 mg/day).MethodsProportion of days covered (PDC) was calculated in 108 Gout App (Gout APP) trial participants with at least two recorded ULT dispensings in an approximately 12‐month period before provision of intervention or control apps. Adherence was defined as PDC ≥80%. We measured the correlation between the two methods of calculating PDC using a Wilcoxon signed rank test. Agreement between ULT‐taking status (self‐reports) and ULT‐dispensed status (PBS records) was tested with Cohen's kappa (κ), and positive and negative percent agreement.ResultsAllopurinol was prescribed in 93.5% of participants taking ULT. Their self‐reported mean daily dose (SD) was 291 (167) mg/day. Mean PDC (SD) for allopurinol was 83% (21%) calculated using self‐reported dose, and 63% (24%) using WHO's DDD. Sixty‐three percent of allopurinol users were identified as adherent (PDC ≥80%) using self‐reported dose. There was good agreement between self‐reported ULT use and PBS dispensing claims (κ = 0.708, P < .001; positive percent agreement = 90%, negative percent agreement = 82%).ConclusionsParticipant‐reported allopurinol daily doses, in addition to PBS dispensing claims, may enhance confidence in estimating PDC and adherence compared to using DDD. This approach improves adherence estimations from pharmaceutical claims datasets for medications where daily doses vary between individuals or where there is a wide therapeutic dose range.

show abstract

Section: Discussionsupporting

confidence: 85%

Section: Discussionmentioning

confidence: 99%

Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

Schulz,

Coleshill,

Day

et al. 2024

Brit J Clinical Pharma

View full text Add to dashboard Cite

show abstract

Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout

Schulz,

Day,

Coleshill

et al. 2024

Clin Rheumatol

View full text Add to dashboard Cite

This study aimed to examine psychometric properties of the Adherence to Refills and Medications Scale (ARMS) in people with gout. We conducted exploratory factor analysis (EFA) and tested internal consistency (ordinal and Cronbach’s alpha coefficients) and agreement (intraclass correlation coefficient (2,1)) in ARMS scores across three timepoints (baseline, 6, and 12 months) in 487 people with gout. The Kruskal–Wallis test, Spearman’s rank, Kendall’s tau-b correlations, and logistic regression were used to examine the criterion-related validity of the ARMS and factors associated with the ARMS. EFA suggested a one-factor structure, explaining 43.2% of total variance. High internal consistency (ordinal alpha = 0.902 at baseline) and moderate agreement in ARMS scores over time (ICCs > 0.5; p < 0.001) were observed. Lower ARMS scores (indicating better adherence) predicted achieving target serum urate (OR, 0.89; 95% CI, 0.83–0.95; p < 0.001), but not urate-lowering therapy (ULT) adherence (Proportion of Days Covered (PDC) ≥ 80%) (OR, 0.93; 95% CI, 0.81–1.05; p = 0.261). Negative correlations between ARMS and PDC were not statistically significant (Kendall’s tau-b, r = − 0.126, p = 0.078; Spearman’s rho = − 0.173, p < 0.073). Differences in median ARMS scores (IQR) of 16 (14–20), 13 (12–15), and 17.5 (15–21) in three groups of participants who reported (1) not taking ULT, (2) taking ULT and adherent, and (3) taking ULT but not adherent, respectively, were statistically significant (p < 0.001). Age was the only patient factor independently associated with optimal adherence (ARMS score = 12) (OR, 1.91; 95% CI, 1.50–2.43; p < 0.001). The ARMS is a reliable and valid measure of medication adherence behaviours in people with gout, justifying its use in gout medication adherence research. Key Points• Valid, practical, and efficient methods of measuring adherence to medications are needed in people with gout.• Commonly used medication adherence questionnaires have limited validity or have not been validated in people with gout.• The Adherence to Refills and Medications Scale (ARMS) has been proven valid and practical in many chronic illnesses but has not been validated in people with gout.• We showed the ARMS is valid and reliable for use in people with gout.

show abstract

Utility of the Morisky Medication Adherence Scale in gout: a prospective study [Corrigendum]

Cited by 2 publications

References 0 publications

Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

Estimation of adherence to urate‐lowering therapy in people living with gout using Australia's Pharmaceutical Benefits Scheme and patient‐reported dosing

Psychometric evaluation of the Adherence to Refills and Medications Scale (ARMS) in Australians living with gout

Contact Info

Product

Resources

About